https://www.selleckchem.com/products/v-9302.html
tion. However, prior to the publication of any possible future randomized controlled trials, meta-analysis of case reports and case series may provide some evidence. We were unable to identify any relevant trials on the efficacy and safety of rituximab for treating inhibitors in people with hemophilia. The research evidence available is from case reports and case series. Randomized controlled trials are needed to evaluate the efficacy and safety of rituximab for this condition. However, prior to the publication of any possible future ran